Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center
PDF
Cite
Share
Request
Original Article
VOLUME: 26 ISSUE: 3
P: 155 - 160
December 2020

Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center

Arch Epilepsy 2020;26(3):155-160
1. Department of Neurology, Istanbul University İstanbul Faculty of Medicine, İstanbul, Turkey
No information available.
No information available
Received Date: 23.01.2020
Accepted Date: 21.02.2020
PDF
Cite
Share
Request

ABSTRACT

Objectives:

This retrospective study aimed to overview the efficacy and side effects of clobazam in patients with drug-resistant epilepsy who were followed in a tertiary epilepsy center.

Methods:

The patients who had been started clobazam as add-on therapy and have been followed for at least one year were recruited to participate in this study. The clinical, electrophysiologic and imaging features of the patients were reviewed. The side effects and efficacy of clobazam were noted.

Results:

Twelve patients with drug-resistant epilepsy who had focal epilepsy with structural etiology in nine, focal epilepsy with unknown etiology in one, combined focal and generalized epilepsy in one and epilepsy with myoclonic absences in one were included in this study. All patients had at least two antiepileptic drugs with moderate to high doses before clobazam therapy. The side effects were sedation, irritability and blurred vision in three patients. Two patients became seizure-free and seven patients had improved remarkably (≥50% seizure reduction). Only one patient discontinued the drug because of the side effects.

Conclusion:

Our results provide evidence in the efficacy of clobazam as add-on therapy in patients with drug-resistant epilepsy.

Keywords:
Antiepileptic drug, clobazam, drug-resistant epilepsy, medically refractory